atezolizumab,paclitaxel,gemcitabine
roche
['vedo', 'docetaxel', 'nivolumab', 'methotrexate', 'pembro', 'atezo', ' vedo', 'cisplatin', 'imvigor130', 'paclitaxel', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'carboplatin', 'vinflunine', 'nivo', 'gemcitabine']
final os of atezo mono vs chemo in untreated locally adv or muc: ph 3 imvigor130 #gu23 atezo vs plt/gem: os itt: hr 0.98, 95% ci 0.82, 1.16 cis-inelig pd-l1 os: hr 0.56, 95% 0.34, 0.91 next sub rx: 46% v 47% orr: 24.2% vs 44.4% 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday